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neurons, and compared with control neurons to identify 
disease-relevant phenotypes. Expanded GGGGCC repeats 
exhibit instability during reprogramming and neuronal 
differentiation of iPSCs. RNA foci containing GGGGCC 
repeats were present in some iPSCs, iPSC-derived human 
neurons and primary fibroblasts. The percentage of cells 
with foci and the number of foci per cell appeared to be 
determined not simply by repeat length but also by other 
factors. These RNA foci do not seem to sequester several 
major RNA-binding proteins. Moreover, repeat-associ-
ated non-ATG (RAN) translation products were detected 
in human neurons with GGGGCC repeat expansions and 
these neurons showed significantly elevated p62 levels and 
increased sensitivity to cellular stress induced by autophagy 
inhibitors. Our findings demonstrate that key neuropatho-
logical features of FTD/ALS with GGGGCC repeat expan-
sions can be recapitulated in iPSC-derived human neurons 
and also suggest that compromised autophagy function 
may represent a novel underlying pathogenic mechanism.
Keywords ALS · Autophagy · C9ORF72 · FTD · 
Hexanucleotide repeats · iPSCs · Neurodegeneration · 
Neurons · p62 · RAN translation · RNA foci
Introduction
Frontotemporal dementia (FTD), the second most common 
form of presenile dementia, is associated with focal atrophy 
of the frontal or temporal lobes [9]. FTD shares extensive 
clinical, pathological, and molecular overlap with amyo-
trophic lateral sclerosis (ALS), a neurodegenerative dis-
ease that has devastating effects on motor neurons in the 
spinal cord and on frontal neurons in the brain [37]. Strik-
ingly, the RNA-binding proteins, TDP-43 and FUS, are 
Abstract The recently identified GGGGCC repeat expan-
sion in the noncoding region of C9ORF72 is the most com-
mon pathogenic mutation in patients with frontotemporal 
dementia (FTD) or amyotrophic lateral sclerosis (ALS). 
We generated a human neuronal model and investigated 
the pathological phenotypes of human neurons containing 
GGGGCC repeat expansions. Skin biopsies were obtained 
from two subjects who had >1,000 GGGGCC repeats in 
C9ORF72 and their respective fibroblasts were used to 
generate multiple induced pluripotent stem cell (iPSC) 
lines. After extensive characterization, two iPSC lines from 
each subject were selected, differentiated into postmitotic 
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major pathological proteins in both FTD and ALS [6, 26, 
33, 34, 45]. Moreover, both FTD and ALS can be caused 
by mutations in the same gene, such as those encoding 
valosin-containing protein (VCP) [22, 46], charged multi-
vesicular body protein 2B (CHMP2B) [11, 42], ubiquilin 2 
(UBQLN2) [14], and chromosome 9 open reading frame 72 
(C9ORF72) [12, 39].
The GGGGCC repeat expansion in the noncoding 
region of C9ORF72 is the most common known pathogenic 
mutation in FTD and ALS [12, 30, 39]. C9ORF72 encodes 
an uncharacterized protein, and it is not known how 
GGGGCC repeat expansions cause FTD/ALS. It has been 
proposed that C9ORF72 haploinsufficiency, RNA toxicity, 
or both are potential pathogenic mechanisms in patients 
with C9ORF72 repeat expansions [12, 19, 39]. Whether 
RNA foci are present in neurons of FTD and ALS patients 
with GGGGCC repeat expansions is controversial [12, 
41]. Recently, repeat-associated non-ATG (RAN) trans-
lation has been detected in a subset of neurons in patient 
brains, raising the possibility that neurotoxicity of di-pep-
tide repeats may be a third major pathogenic mechanism in 
these patients [7, 32].
So far, understanding of pathogenic mechanisms has 
been hampered by the lack of suitable cellular or ani-
mal model of GGGGCC repeat expansion. Traditional 
approaches to disease modeling have a number of poten-
tial intrinsic limitations, for instance, a disease gene is 
often overexpressed. Moreover, long repeat sequences are 
often unstable, posing a significant technical challenge for 
molecular cloning and disease modeling of C9ORF72-
related FTD/ALS in animals. Induced pluripotent stem cell 
(iPSC) technology allows mechanistic studies of disease 
genes in their native genetic contexts [49]. Indeed, iPSC 
models of several neurodegenerative diseases have been 
established [3, 15, 16, 20, 21, 24, 35, 43]. In this study, we 
generated multiple iPSC lines from two members of the 
Vancouver, San Francisco, and Mayo family 20 (VSM-20 
family) [12] with long GGGGCC repeats and investigated 
the neuropathological features and novel disease mecha-
nisms in patient-derived iPSCs and human neurons.
Materials and methods
Human subjects
Skin biopsies were obtained from two VSM-20 family 
members, one with predominantly bvFTD, and the other 
a presymptomatic carrier. To protect their privacy, they are 
simply named as carrier 1 and carrier 2 without disclos-
ing their personal information. Frozen tissues, consisting 
of 1 cm3 blocks of superior frontal gyrus, were obtained 
from two middle-aged males with bvFTD due to C9ORF72 
hexanucleotide repeat expansion. The study was approved 
by the Institutional Review Board and Ethics Committees 
at the University of California, San Francisco (UCSF) and 
written informed consent was obtained from all participants 
in this study.
Isolation of primary human skin fibroblasts and generation 
of iPSCs
Skin biopsies were cut into small pieces and placed on cul-
ture dishes to allow fibroblasts to expand. The cells were 
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10 % fetal bovine serum, 1X nonessential 
amino acids, and penicillin/streptomycin (100 U/ml).
FTD patient-specific iPSCs were generated as described 
[3, 44]. Briefly, fibroblasts (8 × 105 per 100 mm dish) 
were transduced with equal volumes of supernatants from 
cultures of retroviruses expressing human OCT3/4, SOX2, 
KLF4, and c-MYC. The next day, the medium was removed 
and replaced with fresh viral supernatants. Seven days after 
the first infection, cells were collected and seeded (5 × 104 
cells per 100 mm dish) on SNL feeder cells treated with 
mitomycin C. One day later, the medium was replaced with 
iPSC medium containing 4 ng/ml basic fibroblast growth 
factor; thereafter, the medium was changed every other day. 
Five weeks after viral transduction, colonies were picked, 
transferred to 12-well plates coated with Matrigel (BD 
Biosciences), and cultured in mTeSR1 medium (StemCell 
Technologies). For expansion, cells were dissociated with 
1:2 accutase/PBS solution for 1 min at room temperature, 
washed twice with PBS, and scraped with a cell lifter into 
mTeSR1 medium. Larger colonies were further broken up 
by pipetting and transferred to 6-well plates.
Neuronal differentiation and immunocytochemistry
Neuronal differentiation of human iPSC lines and immu-
nocytochemistry on postmitotic neurons were performed as 
described [3].
For neuronal differentiation, iPSC colonies were 
detached with accutase (Millipore) and grown as embryoid 
bodies (EBs) in suspension for 5–6 days in iPSC medium 
in the absence of basic fibroblast growth factor. EBs were 
allowed to attach and form rosettes. Ten-day-old rosettes 
were collected and grown in suspension as neurospheres. 
Neurospheres were dissociated after 3–4 weeks, and the 
cells were placed on glass coverslips (BD Biosciences) or 
plates coated with poly-d-lysine (0.1 mg/ml) and laminin 
(10 μg/ml). Neurons were used after 2–4 weeks in culture.
For in vitro differentiation, EBs were generated as 
described above, grown for 8 days in suspension, placed on 
Matrigel-coated glass coverslips, and allowed to further dif-
ferentiate for 8 days in mTeSR1 medium. Cells migrating 
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out of the attached EBs were stained and analyzed by flu-
orescence microscopy (Olympus IX-70 microscope) for 
markers of the three germ layers. Karyotype analysis was 
done at the Cytogenetic Laboratory, UMASS Memorial 
(Worcester, MA), using standard protocols for G-banding.
For immunocytochemistry, cells were fixed in 4 % para-
formaldehyde (pH 7.4) for 10 min and permeabilized with 
0.2 % Triton X-100. After blocking with 3 % bovine serum 
albumin for 30 min, cells were incubated with primary anti-
bodies for 1 h at room temperature or overnight at 4C. The 
primary antibodies were goat anti-Nanog (R&D Systems; 
1:100), mouse anti-SSEA4 (Abcam; 1:100), rabbit anti-
desmin (Thermo Scientific; 1:100), mouse anti-βIII-tubulin 
(Promega; 1:500), and mouse anti-α-fetoprotein (R&D 
Systems; 1:200), mouse anti-MAP2 (Sigma; 1:500), rabbit 
anti-glial fibrillary acidic protein (Dako; 1:1,000), rabbit 
anti-VGLUT1 (Synaptic Systems; 1:500), rabbit anti-
GABA (Sigma; 1:100), rabbit anti-tyrosine hydroxylase 
(Millipore; 1:500), mouse anti-hnRNP A2/B1 (Santa Cruz 
Biotechnologies; 1:700), goat anti-hnRNP H1 (Santa Cruz 
Biotechnologies; 1:3,000), rabbit anti-hnRNP H2 (Sigma; 
1:300), mouse anti-hnRNP F (Santa Cruz Biotechnologies; 
1:1,000), rabbit anti-TDP43 (Protein Tech Group; 1:100), 
rabbit anti-FUS (Protein Tech Group; 1:300), mouse anti-
nucleophosmin (Abcam; 1:3,000). After three washes with 
PBS, the cells were incubated with AlexaFluor-conjugated 
secondary antibodies (Invitrogen; 1:300) for 1 h at room 
temperature and counterstained with 1 μg/ml Hoechst or 
DAPI. Immunostained cells were examined by fluores-
cence microscopy.
Electrophysiology
Neurons (3–4 weeks in culture) plated on coverslips were 
mounted onto on an upright microscope (BX51WI, Olym-
pus). Neurons were bathed in pH 7.4 oxygenated extra-
cellular solution containing: 125 mM NaCl, 2.5 mM KCl, 
1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2, 26 mM 
NaHCO3, 11 mM d-Glucose. Neurons were visually identi-
fied via infrared (IR) differential interference contrast video 
microscopy with an IR-CCD camera (Olympus). Depolar-
ization-evoked action potentials and spontaneous EPSCs 
were recorded at room temperature using the whole-cell 
configuration of a Multiclamp 700B patch-clamp amplifier 
(Molecular Devices) in current- or voltage-clamp mode, 
respectively. The junction potential between the patch 
pipette and extracellular solution was nullified just prior to 
obtaining a seal on the neuronal membrane. Internal pipette 
solution contained: 121 mM KCl, 4 mM MgCl2, 11 mM 
EGTA, 1 mM CaCl2, 10 mM HEPES, 0.2 mM GTP, and 
4 mM ATP. Signals were filtered at 2 kHz using the ampli-
fier’s four-pole, low-pass Bessel filter, digitized at 10 kHz 
with an Axon Digidata 1,440 A interface and stored on a 
personal computer. Extracellular solution with or without 
CNQX (10 μM) or TTX (0.5 μM) was applied onto neu-
rons by gravity superfusion.
qRT-PCR and northern blot
Total RNA was isolated using RNeasy Kit (Qiagen) and 
500 ng of RNA were reverse transcribed to cDNA using 
TaqMan Reverse Transcription Reagents kit (Applied Bio-
systems) following the manufacturer’s instructions. Quan-
titative PCR was performed using SYBR Green Master 
Mix (Applied Biosystems) and 10 μM of forward and 
reverse primers or TaqMan Gene Expression Master Mix 
and TaqMan primers (C9ORF72 variant 1, Applied Biosys-
tems). Ct values for each sample and gene were normalized 
to GAPDH gene. The 2exp (−ΔΔCt) method was used to 
determine the relative expression of each gene. Primers 
used in this study can be found in Table S1. Analysis of the 
transgenes silencing was performed as described [3].
For northern blot analysis, total RNA (2–5 μg) was 
loaded into a 0.8 % agarose gel containing 1.8 % formal-
dehyde. RNA was transferred to a positively charged nylon 
membrane (Roche) by capillary blotting and crosslinked by 
UV irradiation. The probe recognizing all three C9ORF72 
isoforms was synthesized with T7 RNA polymerase 
(Roche) from cDNAs obtained by PCR with specific prim-
ers (Table S1). RNA probes specifically detecting V2 and 
V3 isoforms were chemically synthesized and 5′ modified 
to add Dig label (sequence in Table S1). Hybridization was 
performed overnight at 62 °C.
Southern blot
Southern blot analysis was performed as described [12] 
with small modifications. Briefly, genomic DNA (10 μg) 
was digested overnight with XbaI, separated by elec-
trophoresis on a 0.8 % agarose gel, transferred to a posi-
tively charged nylon membrane (Roche Applied Science), 
crosslinked by UV, and hybridized overnight at 47 °C with 
a digoxigenin-labeled PCR probe. The 676 bp probe was 
amplified from genomic DNA with specific primers (Table 
S1) and the PCR DIG Probe Synthesis Kit (Roche). The 
probe was denatured at 95 °C for 5 min and added to the 
hybridization mix (EasyHyb granules, Roche). The digox-
igenin-labeled probe was detected with anti-digoxigenin 
antibody and CDP-Star reagent as recommended by the 
manufacturer (Roche).
Fluorescence in situ hybridization
FISH was performed using a Cy3-conjugated (GGCCCC)4 
or (CAGG)6 oligonucleotide probes. Briefly, cells on glass 
coverslips were fixed in 4 % paraformaldehyde for 20 min, 
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permeabilized in 70 % ethanol at 4 °C, incubated with 
40 % formamide/2X SSC for 10 min at room temperature, 
and hybridized for 2 h at 37 °C with a Cy3-conjugated 
(GGCCCC)4 probe (16 ng/ml) in hybridization buffer con-
sisting of 40 % formamide, 2X SSC, 10 % dextran sulfate, 
yeast tRNA (1 mg/ml), and salmon sperm DNA (1 mg/ml). 
The cells were washed once with 40 % formamide/1X SSC 
for 30 min at 37 °C and twice with 1X SSC at room tem-
perature for 30 min. For the RNase A experiments, after 
fixation, cells were incubated with 24 μg/ml RNase A for 
20 min at room temperature.
Stress-induced toxicity and caspase-3 activity assays
Two-week-old neurons were exposed to: tunicamycin, 
rotenone, staurosporine, chloroquine, 3-methyladenine or 
DMSO for 24 h. Cell viability and caspase-3-like activ-
ity were determined as described [3]. Cell viability values 
were expressed as the percentage of the untreated cells or 
cells treated with DMSO (control) and caspase-like activ-
ity was calculated as the increase above control (untreated 
cells).
Western blotting
Fifteen micrograms of protein were separated by SDS-
PAGE followed by immunoblotting with mouse anti-p62 
(1:500, BD Biosciences), mouse anti-Glyceraldehyde-
3-Phosphate Dehydrogenase (GAPDH, 1:3,000, Mil-
lipore) and HRP-conjugated anti-mouse second antibody 
(1:5,000). Immunoblots were developed by SuperSig-
nal West Pico Chemiluminescent substrates (Thermo 
Scientific).
Pull-down of GGGGCC-binding proteins from mouse 
brain lysates
300 μg of nuclear extract from mouse brain was passed 
over an in vitro transcribed and biotinylated (Biotin 11 
CTP, Perkin Elmer) (GGGGCC)30 RNA bound to strepta-
vidin coated magnetic beads (Dynabeads M-280 streptavi-
din, Invitrogen) in the presence of 20 mM Hepes, 300 mM 
NaCl, 2 mM MgCl2, 0.01 % NP40, 1 mM DTT and pro-
tease inhibitor (PIC, Roche). The magnetic beads with 
immobilized RNA and its bound proteins were washed 
three times with the binding buffer and bound proteins 
were eluted by boiling 3 min the in sample buffer prior to 
4–12 % SDS-PAGE (NuPAGE 4–12 % Bis–Tris Gel, Inv-
itrogen) separation and silver staining (SilverQuest, Invit-
rogen). The protein bands were excised digested and iden-
tified using NanoESI_Ion Trap (LTQ XL Thermo Fisher 
Scientific).
Detection of RAN translation products
Sequential extractions of neuronal cell pellets were per-
formed as described by Winton et al. [48]. Human neuronal 
cell pellets were lysed in cold RIPA buffer and sonicated 
on ice. Cell lysates were then cleared by centrifugation at 
100,000 g for 30 min at 4 °C. The supernatant was col-
lected and protein concentration was determined by BCA 
assay. To prevent carry-over, the resulting pellet was resus-
pended in RIPA buffer, re-sonicated and re-centrifuged. 
The RIPA-insoluble pellet was then extracted using 7 M 
urea buffer (volume of buffer adjusted based on protein 
concentration of RIPA soluble samples), sonicated and 
centrifuged at 100,000 g for 30 min at 22 °C. The protein 
concentration of the urea soluble supernatant was deter-
mined by Bradford assay. Two micrograms of urea soluble 
sample was directly dotted onto a nitrocellulose membrane, 
which was then dried, blocked, and finally probed with 
anti-GP rabbit polyclonal antibody. The anti-GP antibody 
was generated by immunizing a rabbit with C-Ahx-GPG-
PGPGPGPGPGPGP-amide. Specificity of antibody was 
verified by immunoassay and by Western blot using previ-
ously described methods [7]. First, (GP)8 peptide or (GR)8 
peptide (negative control) were diluted in Tris-buffered 
saline (TBS) and added to duplicate wells (30 μl/well) of a 
96-well Meso Scale Discovery (MSD) assay plate. Follow-
ing overnight incubation at 4 °C, wells were washed with 
TBS containing 0.2 % Tween 20 (TBSTw) and blocked 
with TBSTw + 3 % non-fat milk. Blocking buffer contain-
ing anti-GP and SULFO-TAG™-rabbit secondary antibody 
was then added at 25 μl/well. Following a 2 h incubation 
and final washes, anti-GP binding to immobilized peptides 
was evaluated by adding MSD Read Buffer and measuring 
light emission at 620 nm upon electrochemical stimulation 
using the MSD Sector Imager 2,400.
For Western blotting, HEK293T cells were transfected 
using LipofectamineTM 2000 with pEGFP plasmids into 
which oligonucleotides of 5 repeats of GP, GR, or GA were 
inserted. Cell lysates were resolved by 10 % Tris–Glycine 
SDS-PAGE (Invitrogen) and transferred to nitrocellulose 
membranes for probing with anti-GP. Blots were stripped 
and reprobed for GFP (Zymed). Pre-immune serum was 
tested against the peptide antigen and confirmed negative.
Statistical analysis
Values are expressed as mean ± SEM. The significance 
of differences among multiple groups was determined 
with a one-way analysis of variance (ANOVA) followed 
by a Tukey–Kramer post hoc test (GraphPad Prism ver-
sion 6.02). Differences were considered significant at 
p < 0.05.
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Results
Generation and characterization of iPSCs from two 
members of the VSM-20 family
Two members of the VSM-20 family with FTD/ALS linked 
to chromosome 9p [8, 12] consented to skin biopsy. To 
reprogram primary fibroblasts into putative pluripotent 
stem cells, we transduced the cells with four transcription 
factors (OCT3/4, SOX2, KLF4, and CMYC) as described 
[3, 44]. Five weeks after transduction, 20 embryonic stem 
cell-like colonies per individual were picked and propa-
gated under feeder-free conditions.
Silencing of the transduced transcription factors after 
reprogramming was confirmed by quantitative RT-PCR 
(qRT-PCR). Silencing was complete when the total expres-
sion level of each factor was not different from that of 
the endogenous gene. Based on this analysis, two lines 
from each carrier were selected for further characteriza-
tion: lines 5 and 6 from VSM-20 family member 1, and 
lines 1 and 11 from member 2 (Fig. 1a). All four lines 
also expressed the embryonic stem cell markers OCT3/4, 
SOX2, NANOG, and teratocarcinoma-derived growth fac-
tor 1 (TDGF1, or CRIPTO) at levels similar to those in 
human embryonic stem cell line H9 (Fig. 1a, b). Immu-
nofluorescence staining showed high-level expression of 
the pluripotency markers SSEA4 and NANOG (Fig. 1c). 
The pluripotency of the iPSCs was also evaluated in vitro 
through the formation of EBs. All four iPSC lines sponta-
neously differentiated into cell types of the three embry-
onic germ layers, as indicated by expression of the specific 
markers α-fetoprotein (AFP, endoderm), desmin (meso-
derm), and βIII-tubulin (ectoderm) (Fig. 1d). Moreover, all 
these iPSC lines had a normal karyotype (Fig. 1e). These 
findings indicate successful reprogramming of fibroblasts 
with C9ORF72 repeat expansion to a pluripotent state. All 
the experiments below used iPSC lines between passage 
24 and 34.
Evidence for GGGGCC repeats instability during iPSC 
reprogramming
After the publication of studies showing that GGGGCC 
repeat expansion is the disease-causing mutation in the 
VSM-20 family and other patients with FTD/ALS [12, 
39], we first performed southern blot analysis to confirm 
the presence of the repeat expansion in skin fibroblasts 
from these two members of the VSM-20 family. Consist-
ent with results in lymphoblasts of other VSM-20 fam-
ily carriers [12], fibroblasts from both family members 
had both wildtype (2.3 kb) and expanded alleles (Fig. 2). 
While fibroblasts from 5 healthy and FTD patients without 
repeat expansion had wildtype allele only on the southern 
blot (data not shown). Thus, we designated them C9ORF72 
mutation carriers. Carrier 1 had a single mutant band cor-
responding to ~1,000 repeats. Carrier 2 had three mutant 
bands, estimated to contain ~1,600, 730, and 650 repeats, 
suggesting mixed populations of fibroblasts harboring 
repeats of different lengths. In this experiment and all of 
the following experiments, iPSCs derived from a healthy 
control and a sporadic FTD subjects were used which 
were already published recently [3]. CAG repeat expan-
sion in ataxin 2 is associated with ALS in some patients 
[17]. We found the number of CAG repeats in both carri-
ers was similar to that in controls (data not shown), ruling 
out the possibility of a general repeat expansion in different 
genes in these carriers. After reprogramming of fibroblasts, 
the expanded GGGGCC alleles were also found in all the 
iPSCs lines we analyzed but not in control iPSCs (Fig. 2).
To determine the repeat length in iPSCs, we first com-
pared fibroblasts with the corresponding derived iPSC 
lines for each carrier. For carrier 1, reprogramming did not 
seem to affect repeat length in line 6, as the band corre-
sponding to the expanded allele has the same size as the 
band for fibroblasts. The presence of a single predominant 
repeat size in carrier 1 fibroblasts and iPSC line 6 suggests 
a certain degree of intrinsic stability. However, in line 5, 
the repeat length was about 200 repeats longer than the 
length in the fibroblasts (Fig. 2). Since Southern blot can 
only detect the most abundant species, and each iPSC line 
is clonally derived from one single fibroblast, line 6 was 
most likely originated from one fibroblast containing the 
more abundant repeat size, whereas line 5 could have been 
originated from a fibroblast containing a rarer repeat size. 
Nevertheless, it is also possible that the change in repeat 
length in line 5 occurred due to instability of the expanded 
allele during iPSC reprogramming. The latter possibility is 
supported by the observation of iPSCs derived from car-
rier 2 (Fig. 2). Line 11 of carrier 2 had the same pattern 
and repeat lengths as the parental fibroblasts, whereas the 
repeat length of multiple bands was greatly reduced in line 
1. Since a single fibroblast contains only one mutant allele 
with one defined repeat length, the population of iPSCs 
with either similar (line 11) or different (line 1) allele com-
binations from the original population of fibroblasts is most 
likely generated due to regulated instability of the expanded 
allele during clonal expansion.
Differentiation of iPSCs with GGGGCC repeat expansions 
into functional neurons
The neuronal differentiation protocol for iPSC lines was 
identical to that in our study on human embryonic stem 
cells [13] and progranulin iPSCs [3]. In order to model 
FTD, we used this protocol to generate postmitotic neu-
rons derived from neuronal progenitor cells that express 
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the telencephalon marker BF1 (FOXG1) [29]. We did not 
observe any obvious difference in the neuronal differentia-
tion potential between iPSCs with repeat expansions and 
controls (Fig. 3a). The percentage of cells positive for the 
neuronal marker microtubule-associated protein 2 (MAP2, 
approximately 80 %) or the glial marker glial fibrillary 
acidic protein (GFAP, <5 %) was similar in controls and 
repeat carriers (Fig. 3b, c). In addition, we determined 
whether the presence of GGCCCC repeats affects the type 
of neurons obtained with this protocol. More than 30 % 
of the MAP2+ cells were also positive for the glutamater-
gic marker, VGLUT1 (Fig. 3d), and <10 % of cells were 
GABA+ inhibitory neurons or TH+ dopaminergic neurons 
(Fig. 3e, f). Because there was no significant difference 
between the percentages of neurons differentiated from 
control and repeat carriers, we concluded that the repeat 
expansions do not significantly interfere with this neuronal 
differentiation process.
Fig. 1  Generation and characterization of iPSC lines from carri-
ers of C9ORF72 expanded repeats. Total and endogenous (Endo) 
mRNA levels of the reprogramming factors KLF4, CMYC, SOX2, 
and OCT4 in iPSC lines from carriers 1 and 2 relative to the values in 
human embryonic stem cell line H9 were assessed by qRT-PCR. Val-
ues are mean ± SEM (a). The expression of the pluripotency markers 
NANOG and TDGF1 (or CRIPTO) was measured at the mRNA level. 
The values from H9 cells were set to 1. Values are mean ± SEM (b). 
Immunofluorescence analysis of pluripotency markers NANOG and 
SSEA4 in iPSC lines from carriers 1 and 2 is shown and cell nuclei 
were counterstained with Hoechst (blue). Scale bar 50 μm (c). After 
in vitro spontaneous differentiation of iPSC lines into cells of three 
embryonic germ layers, cells were immunostained with α-fetoprotein 
(AFP, endoderm), desmin (mesoderm), βIII-tubulin (ectoderm), and 
Hoechst (nuclei). Scale bar 50 μm (d). All iPSC lines maintained a 
normal karyotype (e)
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Similar to what we have previously shown for control 
neurons [3], neurons from GGGGCC repeat carriers dis-
played depolarization-evoked action potentials that could 
be blocked by tetrodotoxin (TTX) (Fig. 3g). In addi-
tion, these cells were capable of establishing functional 
synaptic connections as indicated by the inhibition of 
spontaneous AMPA-type glutamate receptor-mediated 
excitatory postsynaptic currents (EPSCs) by CNQX 
(Fig. 3h) and the presence of PSD95 puncta on dendrites 
of these neurons (Fig. S1a). The repeat expansion does 
not seem to affect PSD95 mRNA level (Fig. S1b) or the 
number of PSD95 puncta (Fig. S1c). The effects of both 
TTX and CNQX could be reversed after washout (data not 
shown). These results indicate that postmitotic neurons 
differentiated from iPSCs with C9ORF72 repeat expan-
sions are functional.
We next examined the stability of the GGGGCC repeats 
during neuronal differentiation of iPSCs. Although little or 
no change in repeat length was observed during multiple 
passages of established iPSCs (from 24 to 34 passages), 
remarkably, the repeat number decreased to ~900 in neu-
rons differentiated from iPSC line 6 of carrier 1 (Fig. 4b). 
Moreover, one new band corresponding to 400 repeats 
appeared in neurons differentiated from iPSC line 11 of 
carrier 2 (Fig. 4c). In both cases, iPSCs at passage 24 were 
used. Although it remains to be examined to what extent 
other iPSC lines exhibit such a repeat instability during 
neuronal differentiation, the repeat instability during neu-
ronal differentiation may partially explain the mosaicism in 
repeat length in the brains of two FTD patients harboring 
GGGGCC repeat expansion (Fig. 4d).
RNA foci and RAN translation products are present  
in iPSC-derived human neurons
Nuclear RNA foci containing GGGGCC repeats were 
found in a subset of brain and spinal cord neurons of 
FTD/ALS patients with C9ORF72 repeat expansion but 
others failed to do so [12, 41]. To resolve this controver-
sial issue, we examined iPSCs and human neurons contain-
ing GGGGCC repeat expansions by fluorescence in situ 
hybridization (FISH). First, we confirmed the expression 
of different C9ORF72 RNA variants in iPSCs and iPSC-
derived human neurons. The nomenclature of these variants 
follows the latest in the PubMed in which variant 1 (V1, 
NM 145005.5) corresponds to the mRNA encoding a trun-
cated C9ORF72 protein (isoform b), and variants 2 and 3 
(V2, NM 018325.3 and V3, NM 001256054.1) each encode 
the full length C9ORF72 protein (isoform a). The hexanu-
cleotide repeats are located in the 5′ end of V2 and in the 
first intron of V3. We found that V2 and V3 are expressed 
in iPSCs (Fig. 5a–c, Fig. S2) and iPSC-derived human neu-
rons (Fig. 6a–c). Consistent with a previous report [12], V2 
expression was slightly lower in neurons of repeat expan-
sion carriers than that in two non-carriers (Fig. 6b). We also 
found that on northern blot, neither V1 nor any abnormal 
mRNA species with larger sizes was detectable in iPSCs 
(Fig. S2).
Since C9ORF72 RNA transcripts are expressed in iPSCs 
and iPSC-derived human neurons, we next determined 
whether RNA foci containing GGGGCC repeat expansions 
could be detected. Using a Cy3-conjugated (GGCCCC)4 
oligonucleotide probe, we detected repeat-containing RNA 
foci in all iPSC lines from carrier 1 (Fig. 5e, showing rep-
resentative image from line 6) and carrier 2 (Fig. 5f, repre-
sentative image from line 11); but no foci were detected in 
control iPSCs (Fig. 5d). Similarly, these foci were detected 
in neurons derived from iPSC line 6 from carrier 1 (Fig. 6e) 
and line 11 from carrier 2 (Fig. 6f) but not in control neu-
rons (Fig. 6d). We confirmed that foci are indeed made of 
RNA as after RNase treatment no foci could be detected 
(Fig. 5g, h). To confirm that these foci are specific to the 
(GGCCCC)4 oligonucleotide probe, we used a (CAG)8 
probe specific for CTG repeats associated with myotonic 
dystrophy type 1 (data not shown) and a (CAGG)6 probe 
specific for CCTG repeats associated with myotonic dys-
trophy type 2. No foci were detected in iPSCs (Fig. 5i) or 
iPSC-derived human neurons (data not shown). To further 
demonstrate that these RNA foci are specific to carriers 
with GGGGCC repeat expansions, we examined primary 
fibroblasts from 5 carriers and 5 subjects with no disease 
or other FTD mutations. RNA foci containing GGGGCC 
repeats were found in some fibroblasts of all five carriers 
but were absent in controls or patients with FTD due to 
mutations in MAPT or GRN (Fig. S3).
Fig. 2  Southern blot analysis of C9ORF72 alleles in fibroblasts and 
two iPSC lines (passage 24) derived from each individual. One repre-
sentative blot is shown here
392 Acta Neuropathol (2013) 126:385–399
1 3
Discrete and punctate RNA foci containing GGGGCC 
repeats were mostly found in the nucleus. Occasion-
ally a few foci were seen outside the nucleus, as in other 
repeat diseases [47]. These RNA foci are similar in size 
to PML nuclear bodies but they do not overlap (Fig. S4). 
Because GGGGCC-containing RNA foci are not present 
in all iPSCs or human neurons and are relatively small in 
size, it is unlikely these foci in human cells under these 
culture conditions can impair RNA metabolism through 
sequestering sufficient amounts of some abundantly 
expressed nuclear RNA-binding proteins. Indeed, among 
the top 30 RNA-binding proteins that we identified in 
mouse brain extracts to bind to biotinylated (GGGGCC)30 
RNA in vitro, 8 are hnRNP proteins. We found H1 (Fig. 
S4) and H2 (Fig. S5) were not sequestered into the foci 
or mislocalized in iPSCs, even though transiently over-
expressed GGGGCC repeats could artificially seques-
ter these proteins under non-physiological conditions 
Fig. 3  GGGGCC repeats do not affect neuronal differentiation of 
iPSCs. MAP-2-positive neurons with or without GGGGCC repeat 
expansions after neuronal differentiation, using methods described 
in Almeida et al. [3]. Nuclear staining is shown in blue. Scale bar 
50 μm (a). The percentage of MAP-2-positive neurons (b) and 
GFAP-positive astrocytes (c) in 2 week-old cultures are shown. Cells 
positive for VGLUT1 (d), GABA (e), and TH (f) (glutamatergic, 
GABAergic and dopaminergic markers, respectively) were counted 
as a percentage of MAP-2+ cells. On average, 200 cells were ana-
lyzed per experiment (n = 3 independent cultures). Values are 
mean ± SEM. Representative depolarization-evoked action potentials 
from neurons at baseline and after 2 min application of tetrodotoxin 
(0.5 μM) are shown. Action potentials were elicited by current injec-
tions from +400 to 0 pA in 100 pA steps (n = 10–14 for each line) 
(g). Representative spontaneous EPSCs at baseline and after 2 min 
application of CNQX (10 μM). Neurons were held at −60 mV under 
voltage-clamp (n = 10–11 from each line) (h)
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(Fig. S6). Other major RNA/DNA-binding proteins of 
interest include FUS, TDP-43, NONO, FMRP, nucleo-
lin and nucleophosmin. The latter two interact with each 
other and are known to bind to G-rich RNAs and DNA 
G-quadruplexes [1, 10]. Interestingly, recent studies sug-
gest that GGGGCC repeats associated with FTD/ALS 
form RNA G-quadruplexes [18, 38]. However, nucle-
ophosmin was not sequestered in GGGGCC repeats-
containing foci with seemingly normal subcellular dis-
tribution in iPSCs (Figs. S4, S5) or in human neurons or 
primary fibroblasts derived from GGGGCC repeat expan-
sion carriers (data not shown). Similarly, no change in 
subcellular localization was observed for FUS, TDP-43, 
hnRNPA2/B1, hnRNP F, and other RNA-binding proteins 
in iPSCs (Figs. S4, S5). Thus, these foci may not seques-
ter sufficient quantity of these or other abundant nuclear 
RNA/DNA-binding proteins to cause their mislocalization 
in these patient cells, at least under the culture conditions 
used here.
Repeat-containing RNA foci were not found in all 
cells. For instance, 23 % of iPSCs from line 6 of carrier 
1 and 68 % of those from line 11 of carrier 2 contained 
foci (Fig. 5j), which were abundant in some iPSCs and 
scarce in others. Similarly, GGGGCC repeat-containing 
RNA foci were present in 29 % of MAP2-positive neu-
rons derived from line 6 and 53 % of those from line 11 
(Fig. 6g). Although the length of these repeats cannot be 
manipulated experimentally, we were fortunate to obtain 
iPSC lines with different repeat lengths (Fig. 2). The repeat 
length was substantially higher in line 6 than line 1 (Fig. 2), 
but both the average percentage of iPSCs or neurons with 
foci (Figs. 5j, 6g) and the average number of foci per cell 
(Figs. 5k, 6h) were similar. Moreover, the repeat length in 
line 5 is only slightly higher than that in line 6 (Fig. 2), yet, 
the percentage of cells with foci (Figs. 5j, 6g) and the aver-
age number of foci per cell (Figs. 5k, 6i) are much higher 
in line 5 than line 6. Since these cells were cultured under 
identical conditions, our data indicate that the formation of 
RNA foci containing GGGGCC repeats is determined not 
simply by the number of repeats but also by other genetic 
or epigenetic factors in the parental fibroblast and subse-
quent iPSC clone.
Very recent studies demonstrate that di-peptide repeats 
can be produced specifically in neurons of patients with 
expanded GGGGCC repeats [7, 32]. To examine whether 
this major pathological feature of C9FTD/ALS can also be 
replicated in iPSC-derived human neurons, we performed 
dot blot analysis of RIPA-insoluble protein lysates obtained 
from human neurons with GGGGCC repeat expansions. 
A new anti-Gly-Pro (GP) antibody was generated and its 
specificity was demonstrated (Fig. S7). Indeed, we detected 
very strong expression of GP dipetides in neurons differ-
entiated from two iPSC lines of carrier 1 and to a lesser 
extent in neurons of carrier 2 (Fig. 6i). There is no direct 
positive correlation between repeat length, the number of 
RNA foci and the level of RAN translation; thus, these two 
major neuropathologic phenotypes seem to be independent 
of repeat length and of each other.
Fig. 4  GGGGCC repeats instability during neuronal differentiation 
of iPSCs. Southern blot analysis of iPSC line 20 of control (a), line 
6 of carrier 1 (b), and line 11 of carrier 2 (c) at different passages 
and their differentiated neurons. The asterisks indicate the mutant 
C9ORF72 alleles in neurons. Brains from a control subject and two 
C9ORF72 repeat expansion carriers show repeats of different lengths 
(d)
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Fig. 5  C9ORF72 repeat 
expansions form RNA foci 
in iPSCs. Expression lev-
els of C9ORF72 variant 1 
(NM_145005.5, isoform b) 
(a), variant 2 (NM_018325.3, 
isoform a) (b) and variant 3 
(NM_001256054.1, isoform 
a) (c) in iPSC lines from two 
non-carriers and two expanded 
repeat carriers were assessed by 
qRT-PCR. Fluorescence in situ 
hybridization (FISH) analysis 
was done on control iPSC line 
20 (d), carrier 1 line 6 iPSCs 
(e), carrier 2 line 11 iPSCs 
(f) using a cy3-conjugated 
(GGCCCC)4 probe. RNA foci 
(red) were found in the nucleus 
(blue) of carriers 1 and 2 but 
not in control cells. Treatment 
of iPSCs with RNase A after 
fixation leads to loss of foci 
(h), indicating that the foci are 
indeed made of RNA. Repre-
sentative images of iPSCs from 
carrier 1 (line 5) that were left 
untreated (g) or treated with 
RNase A (h) for 20 min at room 
temperature. Red RNA foci con-
taining GGGGCC repeats; blue 
nuclei (DAPI). Cells did not 
show foci when a Cy3-conju-
gated (CAGG)6 probe was used 
as the negative control probe (i). 
Scale bar 10 μm. Quantifica-
tions of the percentage of iPSCs 
displaying foci (j) and the aver-
age number of foci per cell (k) 
are shown as mean ± SEM
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Human neurons with GGGGCC repeat expansions are 
more sensitive to cellular stress induced by autophagy 
inhibitors
In order to reveal novel pathogenic mechanisms in 
FTD/ALS with GGGGCC repeat expansions, we per-
formed a systematic screen of several inducers of cellular 
stress similar to our study on iPSC-derived human neu-
rons with progranulin deficiency [3]. We found that human 
neurons with GGGGCC repeat expansions were not more 
sensitive to cellular stress induced by rotenone, a com-
plex I inhibitor and inducer of mitochondrial dysfunction, 
tunicamycin, an inhibitor of protein N-glycosylation and 
stressor of endoplasmic reticulum (ER), and staurosporine, 
a broad-spectrum kinase inhibitor (Fig. S8). Interestingly, 
chloroquine, an inhibitor of autophagy [5], decreased cell 
viability of these neurons (Fig. 7a). To confirm this finding, 
we used another known autophagy inhibitor, 3-methylad-
enine (3-MA) [28, 40], and found that human neurons with 
GGGGCC repeat expansions were more sensitive to 3-MA 
treatment than control neurons (Fig. 7b). To validate the 
findings of the cell viability assay (Fig. 7b), we also meas-
ured the activation of caspase-3 as we did before [3]. Con-
sistent with the results of the cell viability assay, human 
neurons with GGGGCC repeat expansions showed greater 
caspase-3 activation in response to 3-MA than control neu-
rons (Fig. 7c). These findings raise the possibility that the 
autophagy function is compromised in these neurons. To 
Fig. 6  C9ORF72 repeat expan-
sions form RNA foci in patient 
iPSCs-derived neurons. Expres-
sion levels of C9ORF72 variant 
1 (NM_145005.5, isoform b) 
(a), variant 2 (NM_018325.3, 
isoform a) (b) and variant 3 
(NM_001256054.1, isoform 
a) (c) in iPSC-derived neurons 
from two non-carriers and two 
expanded repeat carriers were 
assessed by qRT-PCR. Values 
are mean ± SEM,  
*** p < 0.001 (Student’s t test). 
FISH analysis was done on 
control iPSC-derived neurons 
(d), carrier 1 line 6 iPSC-
derived neurons (e), carrier 2 
line 11 iPSC-derived neurons (f) 
using a cy3-conjugated (GGC-
CCC)4 probe. Green MAP2. 
Blue DAPI. Scale bar 10 μm. 
Quantifications of the percent-
age of neurons displaying foci 
(g) and the average number of 
foci per cell (h) are presented as 
mean ± SEM, based on analysis 
of neurons derived from three 
independent differentiation 
experiments. Gly-Pro dipeptide 
repeats are detected by dot blot 
analysis in neurons of carrier 1 
(iPSC lines 5 and 6) and carrier 
2 (iPSC lines 1 and 11) (i)
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provide further support for this notion, we found that p62, a 
known substrate of the autophagy pathway that is a compo-
nent in neuronal inclusions in C9ORF72 patients [4], sig-
nificantly accumulated in human neurons with GGGGCC 
repeat expansions but not in neurons derived from control 
iPSCs or neurons derived from iPSCs of an FTD patient 
with a progranulin mutation (Fig. 7d).
Discussion
In this study, we established multiple iPSC lines with over 
1000 GGGGCC repeats from two members of the VSM-
20 family. The repeat lengths varied among different iPSC 
lines and changed during neuronal differentiation of a 
given iPSC line. Thus, we have established a model sys-
tem for studying repeat instability in the native genetic 
context. RNA foci containing GGGGCC repeats were 
present in some iPSCs, iPSC-derived human neurons, and 
primary fibroblasts of repeat expansion carriers but were 
not found in cells from healthy subjects or FTD patients 
with other genetic mutations. Nuclear RNA foci contain-
ing GGGGCC repeats do not seem to sequester several 
major RNA-binding proteins under the culture condition 
used in this study. Moreover, RAN translation products 
were detected in iPSCs-derived human neurons with repeat 
expansion. The abundance of RAN translation products and 
the percentage of cells with foci were not determined sim-
ply by repeat length but probably also by other factors as 
well. More importantly, our findings on inducers of cellular 
stress imply that a compromised autophagy pathway may 
be a novel pathogenic mechanism.
During iPSC reprogramming, fibroblasts were dissoci-
ated into single cell suspension and plated at a very low 
density, so it is thought each iPSC clone is derived from a 
single fibroblast cell [44]. Thus, it seems certain that line 
6 was derived from a fibroblast with a repeat length iden-
tical to that of most fibroblasts from the carrier (Fig. 2). 
The repeat length in line 5 was higher, perhaps because 
of repeat instability during reprogramming or because 
the parental fibroblast had a repeat length longer than 
that of most fibroblasts of the carrier. In contrast, iPSC 
lines derived from carrier 2 suggest a dynamic instability 
of GGGGCC repeat expansions during reprogramming. 
Fibroblasts from carrier 2 contained repeats of at least 
three different lengths, suggesting a somatic mosaicism. 
Fig. 7  GGGGCC repeat expansions exacerbate susceptibility to inhi-
bition of the autophagy pathway. Cell viability of human neurons 
after exposure to chloroquine (a) and 3-methyladenine (3-MA) (b) 
for 24 h. Values are expressed as a percentage of the untreated cells 
(control) (n = 3 independent cultures) (a, b). Caspase-3-like activ-
ity after exposure to 5 mM 3-MA for 24 h (c). In all panels, values 
are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (One-way 
ANOVA). Representative Western blot showing p62 protein levels in 
neurons of two non-carriers (PGRN S116X: lines 1 and 26, and con-
trol: lines 17 and 20) and two repeat expansions carriers (carrier 1: 
lines 5 and 6, and carrier 2: lines 1 and 11) (d)
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These three alleles seem to be stable and preferred in the 
fibroblast cell population since no other significant bands 
are seen on the southern blot. Thus, the genetic makeups 
of different fibroblasts are not identical. Indeed, human 
skin fibroblasts show somatic copy number mosaicism 
[2]. Interestingly, line 1 had multiple alleles with smaller 
repeat length, strongly indicating repeat instability dur-
ing reprogramming. A non-clonal origin is highly unlikely 
since the probability that two adjacent fibroblasts with rare 
alleles of smaller repeat length were reprogrammed simul-
taneously is very low. Such a change in repeat length could 
well occur before the first passage or during very early pas-
sages, during which it is impossible to do southern blot 
analysis to measure the repeat length due to limited amount 
of samples. Line 11 showed the same complex pattern as 
the parental fibroblasts (Fig. 2), raising the possibility that, 
after clonal expansion of a reprogrammed fibroblast with 
the largest repeat length, the generation of expanded alleles 
with shorter length within the same population of iPSCs is 
re-established as that in fibroblasts. Further studies are war-
ranted to completely rule out other possible explanations. 
However, GGGGCC repeat instability is consistent with 
varying degrees of instability observed in iPSC models of 
other repeat diseases [20, 25, 36].
Another major finding in this study is the presence of 
RNA foci and RAN translation products in iPSCs-derived 
human neurons, recapitulating two major neuropathologi-
cal features of FTD patients with C9ORF72 repeat expan-
sion. Both phenotypes do not seem to show a positive cor-
relation with the repeat length. GGGGCC-containing RNA 
foci formed only in cells from five C9ORF72 repeat expan-
sion carriers but not in cells from controls or patients with 
mutations in MAPT or GRN. Moreover, the percentage of 
cells with foci and the average number of foci per cell did 
not correlate with the maximum length of repeats, sug-
gesting that the detection of these foci is not simply due to 
the presence of higher copies of repeats and that unknown 
genetic factors contribute to the formation of these RNA 
foci. Since whether foci are present in patient brains is 
controversial [12, 41], the detection of RNA foci in iPSCs-
derived patient neurons highlights the importance of under-
standing these structures.
The RNA foci might exert a toxic gain of function by 
sequestering RNA-binding proteins, as described in other 
repeat diseases such as myotonic dystrophies. In contract 
to large nuclear RNA foci [12] and p62+/hnRNP A3+ cyto-
plasmic aggregates in the brains of patients with C9ORF72 
repeat expansion [31], the nuclear RNA foci observed here 
in iPSCs and iPSCs-derived human neurons are relatively 
small in size and several abundant nuclear RNA-binding 
proteins that can bind to and sequester GGGGCC repeats 
in vitro are not mislocalized, at least under the culture 
conditions used in this study. Transiently overexpressed 
GGGGCC repeats did sequester some hnRNP proteins in 
cultured cells (Fig. S6), which may be an experimental 
artifact. Thus, it remains to be determined what proteins 
are sequestered in the GGGGCC-containing RNA foci in 
human neurons under normal or stress culture conditions 
and in patient brains. It is possible that in patient brains, 
the size of RNA foci may increase during disease progres-
sion over decades, leading to the sequestration of sufficient 
quantity of nuclear RNA-binding proteins to impair RNA 
metabolism.
Another remaining question is whether RAN translation 
products are toxic per se. Our findings that human neurons 
with GGGGCC repeat expansions show p62 accumula-
tion and are more sensitive to autophagy inhibitors raise 
the possibility that RAN translation products may directly 
or indirectly impair the autophagy pathway. It is interest-
ing to note that other FTD mutant proteins also disrupt this 
pathway, such as VCP [23] and CHMP2B [27], in which 
further activation of the autophagy pathway may be detri-
mental to neuronal survival [28]. The availability of iPSC-
derived human neurons with GGGGCC repeat expansions 
in patients’ native genetic context will serve as a compel-
ling model to further investigate underlying pathogenic 
mechanisms and broaden our knowledge of this devastating 
disease.
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